Trillium Therapeutics

Clinical stage #ImmunoOncology company developing innovative therapies for the treatment of #cancer. #CD47 $TRIL

[Trillium Therapeutics @Trillium_Tx]

Trillium Therapeutics Receives Final Court Order Approving Arrangement

https://t.co/NOlWX927h9

[Trillium Therapeutics @Trillium_Tx]

Trillium Securityholders Approve Acquisition by Pfizer

https://t.co/yHFoj7GIzW

[Trillium Therapeutics @Trillium_Tx]

We are proud to announce that our CEO, Jan Skvarka, is a finalist for the 2021 “Executive of the Year (Development stage or companies with market cap <$5bn)” Scrip Award.

Congrats to Jan!

@Pharma_Scrip #ScripAwards

[Trillium Therapeutics @Trillium_Tx]

We are humbled to be a finalist in the Citeline “Most Successful Early Phase Research (Preclinical & Phase I)” category.

Congratulations to all finalists!

@Citeline_Awards #Citeline_Awards #CD47

[Trillium Therapeutics @Trillium_Tx]

We are excited to announce that we have entered into a definitive agreement under which #Pfizer will acquire @Trillium_Tx.

Read the full PR here: https://t.co/AFUKVNGOEp

[Trillium Therapeutics @Trillium_Tx]

Trillium Therapeutics Reports Second Quarter 2021 Operating and Financial Results

https://t.co/TALDMUsiwf

[Trillium Therapeutics @Trillium_Tx]

Trillium Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidine and Venetoclax in TP53-Wild Type Acute Myeloid Leukemia

#CD47 #AML #Immunooncology

https://t.co/mKIUhE0mUX

[Trillium Therapeutics @Trillium_Tx]

Trillium Therapeutics Appoints Catherine Mackey, Ph.D., to Its Board of Directors

https://t.co/O2EocCS794

[Trillium Therapeutics @Trillium_Tx]

First patient dosed in Ph1b/2 study of TTI-621+Dox in Leiomyosarcoma

#CD47 #Leiomyosarcoma

https://t.co/pKTQIbusC2

[Trillium Therapeutics @Trillium_Tx]

In case you missed it... Trillium Therapeutics joins Russell 2000® and 3000® indices.

https://t.co/TOgSO4DKc3

[Trillium Therapeutics @Trillium_Tx]

Trillium Therapeutics Reports First Quarter 2021 Operating and Financial Results

https://t.co/0re0bFM5lx

[Trillium Therapeutics @Trillium_Tx]

We have built a robust foundation for advancing into a Phase 1b/2 program – a foundation of two highly differentiated CD47 assets with monotherapy proof-of-concept across several lymphoma indications.
#CD47 #ImmunoOncology

https://t.co/LEUeiBcn4s

[Trillium Therapeutics @Trillium_Tx]

https://t.co/K0fyICzKcR

[Trillium Therapeutics @Trillium_Tx]

Our R&D Day is next week. The agenda will include a clinical update for TTI-622 and TTI-621, new strategic priorities in terms of target indications and drug combinations across hematologic malignancies and solid tumors, and updated milestones and guidance for 2021.

[Trillium Therapeutics @Trillium_Tx]

R&D Day set for April 28. Trillium will provide data updates, and kick off our next chapter with strategic priorities across heme malignancies and solid tumor indications #ImmunoOnc #Oncology

https://t.co/EEggKwdLNn

[Trillium Therapeutics @Trillium_Tx]

$TRIL Corporate Presentation updated Dec. 7, 2020

https://t.co/39RSUGFITe

[Trillium Therapeutics @Trillium_Tx]

$TRIL presented clinical data at the 62nd ASH Annual Meeting & provides guidance for 2021

https://t.co/U8MOlm2oA6

[Trillium Therapeutics @Trillium_Tx]

$TRIL ASH Investor Call

https://t.co/JO0mihtAsj

[Trillium Therapeutics @Trillium_Tx]

$TRIL to Present Clinical Data at the 62nd American Society of Hematology Annual Meeting

https://t.co/nKSTDbdeLv

[Trillium Therapeutics @Trillium_Tx]

$TRIL Reports Third Quarter 2020 Financial & Operating Results

https://t.co/TucypyCrgm